Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genflow Biosciences Plc ( (GB:GENF) ) just unveiled an announcement.
Genflow Biosciences Plc has decided to terminate a previously announced subscription and instead raised £440,000 through an alternative transaction involving the issuance of 40 million new ordinary shares to CEO Eric Leire. This decision was made as the alternative is more favorable and less dilutive for shareholders. The new shares will be admitted to trading on the London Stock Exchange, with a total of 493,547,942 shares in issue post-admission. This move reflects confidence in Genflow’s mission to advance its gene therapy programs, with the additional capital supporting near-term objectives.
More about Genflow Biosciences Plc
Genflow Biosciences Plc, founded in 2020 and headquartered in the UK with R&D facilities in Belgium, is a biotechnology company focused on developing gene therapies to slow the aging process. Its lead compound, GF-1002, involves the delivery of a centenarian variant of the SIRT6 gene, showing promising preclinical results. The company is conducting a 12-month proof-of-concept clinical trial on aged dogs and plans to explore GF-1002’s potential in treating MASH, a prevalent chronic liver disease.
Average Trading Volume: 6,858,333
Technical Sentiment Signal: Sell
For an in-depth examination of GENF stock, go to TipRanks’ Overview page.